ReviewNature reviews. Drug discovery2020
Radiopharmaceutical therapy in cancer: clinical advances and challenges.
Review in Nature reviews. Drug discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 442 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
442 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Novel Therapeutic Strategies for Metastatic Prostate Cancer Care.European urology · 2025Pooled it
- Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- PSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: insights from a prospective PET-MRI guided multiregional biopsy study.European journal of nuclear medicine and molecular imaging · 2025Trial
- Deciphering the phenotypic responses toEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Predicting tumour and organ dose in α-radiopharmaceutical therapy: aEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma.bioRxiv : the preprint server for biology · 2026Article
- Recent advances in [Nuclear medicine and biology · 2026Review
- Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Artificial Intelligence Across the Cancer Theranostics Workflow: Critical Appraisal of Current Evidence and Future Clinical Translation.Molecular imaging and biology · 2026Review
- Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy.International journal of molecular sciences · 2026Review
- Nanomaterial-driven spatiotemporal autophagy modulation: The dual-edged sword in precision cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Development of galectin-3 targeted radioimmunoligands for cancer theranostics.Acta pharmaceutica Sinica. B · 2026Article
- Cancer pain.Nature reviews. Disease primers · 2026Review
- Comparative Study of NOTA-Derived Chelators: Synthesis, AlInternational journal of molecular sciences · 2026Article
- Theranostics in Radiation Medicine: Integrating Radiopharmaceutical Therapy and External-Beam Radiotherapy.Journal of clinical medicine · 2026Review
- Stable core-encapsulation of indium-111 in crosslinked polyionic complex micelles and assessment of its biodistribution.EJNMMI radiopharmacy and chemistry · 2026Article
- Tumor microenvironment-mediated hematologic toxicity ofWorld journal of urology · 2026Review
- A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational Analysis of Key Parameters in Lutetium-177 PSMA Therapy.Annals of biomedical engineering · 2026Article
- From Unmet Medical Need to Drug Candidate: A Translational Therapeutic Development Roadmap Illustrated by Dual-Payload Antibody-Drug Conjugates.Biomolecules · 2026Review
- FcRn-Targeted Alpha Therapy Using [Molecular imaging and biology · 2026Article
382 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach to treating many types of cancer. In RPT, radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate by physiological mechanisms. Almost all radionuclides used in RPT emit photons that can be imaged, enabling non-invasive visualization of the biodistribution of the therapeutic agent. Compared with almost all other systemic cancer treatment options, RPT has shown efficacy with minimal toxicity. With the recent FDA approval of several RPT agents, the remarkable potential of this treatment is now being recognized. This Review covers the fundamental properties, clinical development and associated challenges of RPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.